Makes Afrezza inhaled insulin and manufactures Tyvaso DPI, an inhaled pulmonary hypertension drug, for United Therapeutics.
Makes Afrezza inhaled insulin and manufactures Tyvaso DPI, an inhaled pulmonary hypertension drug, for United Therapeutics.
Collects a royalty on United Therapeutics' sales of Tyvaso DPI and also manufactures the product for it, while selling Afrezza itself. Both rest on its Technosphere dry-powder inhalation technology, so the partner's sales and its own plant capacity matter.
Moat: narrow (IP / patents, process know-how). Proprietary Technosphere inhaled-powder platform is patent-protected and manufacturing-intensive to replicate.
Headquarters: Danbury, Connecticut, US · Founded: 1991 · Employees: 592
Size MannKind (MNKD) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.31B, the 2059th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.07 on 18 Nov 2026.
Performance Over six months the shares gained 25.2%, against -19.0% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 31.7% over the last twelve months (peer median +7.6%); the operating margin is -1.9% (peer median 10.9%).
Valuation It trades at 174.4× forward earnings against a peer median of 15.4× (2nd most expensive of 11).
Capital Return on invested capital runs 11.4 points below its cost of capital (9.3% WACC).
Short interest Short interest is 8.2% of the free float (30 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $413M | $349M | $286M | $199M | $99.8M |
| Revenue growth | — | +22% | +43% | +99% | — |
| Gross profit | $295M | $257M | $209M | $136M | $42.3M |
| EBITDA | $18.0M | $68.5M | $77.6M | $16.4M | -$62.6M |
| Net income | -$74.8M | $5.86M | $27.6M | -$11.9M | -$87.4M |
| Free cash flow | -$78.7M | $13.7M | $32.4M | -$8.54M | -$88.3M |
| Capital expenditure | $12.2M | $4.57M | $9.69M | $42.4M | $7.59M |
| Total debt | $436M | $473M | $157M | $382M | $388M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| MannKind MNKD | $1.31B | +25% | +32% | -2% | 174.4× | n/a |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 29.5× | 6.5% |
| Novo Nordisk A/S NOVO-B.CO | $177B | -6% | +6% | 48% | 11.8× | -0.5% |
| United Therapeutics UTHR | $24.6B | +2% | +2% | 44% | 23.9× | 0.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MNKD | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +31.3% | -4.3% | highest of 20 |
| 6-month return | +25.2% | -19.0% | 4th highest of 20 |
| Distance from 52-week high | -37.5% | -38.9% | 10th highest of 20 |
| Revenue growth (TTM) | +31.7% | +7.6% | 2nd highest of 16 |
| Operating margin | -1.9% | 10.9% | 7th lowest of 16 |
| Forward P/E | 174.4× | 15.4× | 2nd most expensive of 11 |
| ROIC minus cost of capital | -11.4 pp | -1.8 pp | 5th lowest of 16 |
| Net debt / EBITDA | 18.9× | 0.3× | most indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| MannKind MNKD | United States | $1.31B | +25% | +32% | -2% | 174.4× | n/a | n/a |
| Innoviva INVA | United States | $1.31B | -17% | +12% | 38% | 9.5× | -17.2% | +3.9% |
| Ocular Therapeutix OCUL | United States | $1.31B | -26% | -10% | -681% | n/a | n/a | n/a |
| Windward Bio WWB | United States | $1.31B | n/a | n/a | n/a | n/a | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.32B | +36% | +133% | 11% | 48.6× | 25.9% | +23.1% |
| LB Pharmaceuticals LBRX | United States | $1.30B | +43% | n/a | n/a | n/a | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.30B | -24% | +2% | -2% | 60.7× | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.33B | -23% | +16% | 12% | n/a | 10.2% | +18.1% |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.33B | -2% | +9% | -13% | n/a | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 17.7× | -0.4% | -1.3% |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.34B | -15% | +17% | 20% | 13.0× | 3.9% | +22.8% |
| Nanobiotix NANO.PA | France | $1.35B | -32% | -77% | -392% | n/a | n/a | n/a |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 9.1× | 2.5% | +15.5% |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.35B | -51% | +27% | -384% | n/a | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 522.3× | n/a | n/a |
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 11.9× | 3.4% | +27.9% |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 18.6× | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.39B | -19% | +1% | 19% | 12.1× | -9.6% | +4.6% |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |